The contribution of human OCT1, OCT3, and CYP3A4 to nitidine chloride-induced hepatocellular toxicity

Drug Metabolism and Disposition

Volumn 42, Issue 7, 2014, Pages 1227-1234

  Li, Liping ^a   Tu, Meijuan ^a   Yang, Xi ^a   Sun, Siyuan ^a   Wu, Xiaodan ^b   Zhou, Hui ^a   Zeng, Su ^a   Jiang, Huidi ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; NITIDINE; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 3; QUINIDINE; TETRAHYDROPALMATINE; BENZOPHENANTHRIDINE DERIVATIVE; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; OCTAMER TRANSCRIPTION FACTOR 4; POU5F1 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG UPTAKE; ENZYME METABOLISM; HUMAN; HUMAN CELL; LIVER CELL; LIVER TOXICITY; MALE; MDCK CELL LINE; MICHAELIS MENTEN KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; ANIMAL; CELL LINE; DOG; DRUG EFFECTS; LIVER; METABOLISM; SPRAGUE DAWLEY RAT; TOXICITY;

ANIMALS; BENZOPHENANTHRIDINES; CELL LINE; CYTOCHROME P-450 CYP3A; DOGS; HUMANS; LIVER; OCTAMER TRANSCRIPTION FACTOR-3; ORGANIC CATION TRANSPORTER 1; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84903219017     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.056689     Document Type: Article

References (64)

1. Ahlin G, Hilgendorf C, Karlsson J, Szigyarto CA, Uhlén M, and Artursson P (2009) Endogenous gene and protein expression of drug-transporting proteins in cell lines routinely used in drug discovery programs. Drug Metab Dispos 37:2275-2283.
2. Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, and Artursson P (2008) Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem 51:5932-5942.
3. Arthur HR, Hui WH, and Ng YL (1959) An examination of the rutaceae of Hong Kong. Part II. The alkaloids, nitidine and oxynitidine, from Zanthoxylum nitidum. J Chem Soc O:1840-1845.
4. Brouwer KL, Keppler D, Hoffmaster KA, Bow DA, Cheng Y, Lai Y, Palm JE, Stieger B, and Evers R; International Transporter Consortium (2013) In vitro methods to support transporter evaluation in drug discovery and development. Clin Pharmacol Ther 94:95-112.
5. Brown CM, Reisfeld B, and Mayeno AN (2008) Cytochromes P450: a structure-based summary of biotransformations using representative substrates. Drug Metab Rev 40:1-100.
6. Burger H, Zoumaro-Djayoon A, Boersma AW, Helleman J, Berns EM, Mathijssen RH, Loos WJ, and Wiemer EA (2010) Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol 159:898-908.
7. Chen J, Wang J, Lin L, He L, Wu Y, Zhang L, Yi Z, Chen Y, Pang X, and Liu M (2012) Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer. Mol Cancer Ther 11:277-287.
8. Choi JS, Piao YJ, and Kang KW (2011) Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res 34:607-613.
9. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, and Roila F; ESMO Guidelines Working Group (2012) Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 23 (Suppl 7):vii155-vii166.
10. Del Poeta M, Chen SF, Von Hoff D, Dykstra CC, Wani MC, Manikumar G, Heitman J, Wall ME, and Perfect JR (1999) Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. Antimicrob Agents Chemother 43:2862-2868.
11. Deng JW, Song IS, Shin HJ, Yeo CW, Cho DY, Shon JH, and Shin JG (2008) The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics 18:424-433.
12. Donato MT, Lahoz A, Castell JV, and Gómez-Lechón MJ (2008) Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab 9:1-11.
13. Gakunju DM, Mberu EK, Dossaji SF, Gray AI, Waigh RD, Waterman PG, and Watkins WM (1995) Potent antimalarial activity of the alkaloid nitidine, isolated from a Kenyan herbal remedy. Antimicrob Agents Chemother 39:2606-2609.
14. Gatto B, Sanders MM, Yu C, Wu HY, Makhey D, LaVoie EJ, and Liu LF (1996) Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne. Cancer Res 56: 2795-2800.
15. Gómez-Lechón MJ, Lahoz A, Gombau L, Castell JV, and Donato MT (2010) In vitro evaluation of potential hepatotoxicity induced by drugs. Curr Pharm Des 16:1963-1977.
16. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, and Koepsell H (1997) Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16:871-881.
17. Hasannejad H, Takeda M, Narikawa S, Huang XL, Enomoto A, Taki K, Niwa T, Jung SH, Onozato ML, and Tojo A, et al. (2004) Human organic cation transporter 3 mediates the transport of antiarrhythmic drugs. Eur J Pharmacol 499:45-51.
18. Hashizume T, Yoshitomi S, Asahi S, Uematsu R, Matsumura S, Chatani F, and Oda H (2010) Advantages of human hepatocyte-derived transformants expressing a series of human cytochrome p450 isoforms for genotoxicity examination. Toxicol Sci 116:488-497.
19. Heise M, Lautem A, Knapstein J, Schattenberg JM, Hoppe-Lotichius M, Foltys D, Weiler N, Zimmermann A, Schad A, and Gründemann D, et al. (2012) Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer 12:109.
20. Holden JA, Wall ME, Wani MC, and Manikumar G (1999) Human DNA topoisomerase I: quantitative analysis of the effects of camptothecin analogs and the benzophenanthridine alkaloids nitidine and 6-ethoxydihydronitidine on DNA topoisomerase I-induced DNA strand breakage. Arch Biochem Biophys 370:66-76.
21. Hu J, Zhang WD, Liu RH, Zhang C, Shen YH, Li HL, Liang MJ, and Xu XK (2006) Benzophenanthridine alkaloids from Zanthoxylum nitidum (Roxb.) DC, and their analgesic and antiinflammatory activities. Chem Biodivers 3:990-995.
22. Huang JE, Xu YL, and Liu HG (2011) The experimental study on hepatocytes toxicity of nitidine chloride, plumbagin, taxol in vitro. J Guangxi Med Univ 28:192-195.
23. Iwai M, Minematsu T, Li Q, Iwatsubo T, and Usui T (2011) Utility of P-glycoprotein and organic cation transporter 1 double-transfected LLC-PK1 cells for studying the interaction of YM155 monobromide, novel small-molecule survivin suppressant, with P-glycoprotein. Drug Metab Dispos 39:2314-2320.
24. Iwasaki H, Okabe T, Takara K, Toda T, Shimatani M, and Oku H (2010) Tumor-selective cytotoxicity of benzo[c]phenanthridine derivatives from Toddalia asiatica Lam. Cancer Chemother Pharmacol 65:719-726.
25. Ji LL, Zhao XG, Chen L, Zhang M, and Wang ZT (2002) Pyrrolizidine alkaloid clivorine inhibits human normal liver L-02 cells growth and activates p38 mitogen-activated protein kinase in L-02 cells. Toxicon 40:1685-1690.
26. Jigorel E, Le Vee M, Boursier-Neyret C, Bertrand M, and Fardel O (2005) Functional expression of sinusoidal drug transporters in primary human and rat hepatocytes. Drug Metab Dispos 33:1418-1422.
27. Jones HM and Houston JB (2004) Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab Dispos 32:973-982.
28. Jullian V, Bourdy G, Georges S, Maurel S, and Sauvain M (2006) Validation of use of a traditional antimalarial remedy from French Guiana, Zanthoxylum rhoifolium Lam. J Ethnopharmacol 106:348-352.
29. Khanna I (2012) Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discov Today 17:1088-1102.
30. Koepsell H, Lips K, and Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24:1227-1251.
31. Koepsell H, Schmitt BM, and Gorboulev V (2003) Organic cation transporters. Rev Physiol Biochem Pharmacol 150:36-90.
32. Krishna DR and Klotz U (1994) Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 26:144-160.
33. Lang K, Wagner C, Haddad G, Burnekova O, and Geibel J (2003) Intracellular pH activates membrane-bound Na(+)/H(+) exchanger and vacuolar H(+)-ATPase in human embryonic kidney (HEK) cells. Cell Physiol Biochem 13:257-262.
34. Lautem A, Heise M, Gräsel A, Hoppe-Lotichius M, Weiler N, Foltys D, Knapstein J, Schattenberg JM, Schad A, and Zimmermann A, et al. (2013) Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma. Int J Oncol 42:1297-1304.
35. Li AP (2009) Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome P450 (P450) inhibitors, and P450 inducers. Drug Metab Dispos 37:1598-1603.
36. Liao J, Xu T, Zheng JX, Lin JM, Cai QY, Yu DB, and Peng J (2013) Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway. Int J Mol Med 32:79-84.
37. Liguori MJ, Blomme EA, and Waring JF (2008) Trovafloxacin-induced gene expression changes in liver-derived in vitro systems: comparison of primary human hepatocytes to HepG2 cells. Drug Metab Dispos 36:223-233.
38. Liu HG, Wang BL, Qin SH, and Yang B (2007) Study on G2/M phase arrest and apoptosis of human carcinoma of mouth floor KB cells in vitro induced by nitidine chloride. Lishizhen Med Materia Medica Res 18:2104-2106.
39. Liu LM and Liu HG (2010) Anti-hepatoma activity of nitidine chloride and its effect on topoisomerase. Chin Pharmacol Bull 4:497-500.
40. Liu LM, Liu HG, and Luo D (2009) Antitumor effect of nitidine chloride in vitro and in vivo. Chin J Pharmacol Toxicol 23:214-218.
41. Lu X, Sun D, Chen Z, Ye J, Wang R, Li L, Zeng S, and Jiang H (2011) Evaluation of hepatic clearance and drug-drug interactions of luteolin and apigenin by using primary cultured rat hepatocytes. Pharmazie 66:600-605.
42. Lv P, Huang K, Xie L, and Xu X (2011) Palladium-catalyzed tandem reaction to construct benzo [c]phenanthridine: application to the total synthesis of benzo[c]phenanthridine alkaloids. Org Biomol Chem 9:3133-3135.
43. Mahmoud MF and El Shazly SM (2013) Pioglitazone protects against cisplatin induced nephrotoxicity in rats and potentiates its anticancer activity against human renal adenocarcinoma cell lines. Food Chem Toxicol 51:114-122.
44. Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, Ogawa O, and Inui K (2006) Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 17:2127-2135.
45. Nies AT, Koepsell H, Damme K, and Schwab M (2011) Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol 201:105-167.
46. Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, Zanger UM, Keppler D, Schwab M, and Schaeffeler E (2009) Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 50:1227-1240.
47. Nishimura M and Naito S (2005) Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 20:452-477.
48. Omote H, Hiasa M, Matsumoto T, Otsuka M, and Moriyama Y (2006) The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations. Trends Pharmacol Sci 27:587-593.
49. Pan X, Han H, Wang L, Yang L, Li R, Li Z, Liu J, Zhao Q, Qian M, and Liu M, et al. (2011) Nitidine chloride inhibits breast cancer cells migration and invasion by suppressing c-Src/FAK associated signaling pathway. Cancer Lett 313:181-191.
50. Rendic S and Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413-580.
51. Schaefer O, Ohtsuki S, Kawakami H, Inoue T, Liehner S, Saito A, Sakamoto A, Ishiguro N, Matsumaru T, and Terasaki T, et al. (2012) Absolute quantification and differential expression of drug transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in cultured primary human hepatocytes. Drug Metab Dispos 40:93-103.
52. Sergent T, Dupont I, Van der Heiden E, Scippo ML, Pussemier L, Larondelle Y, and Schneider YJ (2009) CYP1A1 and CYP3A4 modulation by dietary flavonoids in human intestinal Caco-2 cells. Toxicol Lett 191:216-222.
53. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
54. Sun S, Wang K, Lei H, Li L, Tu M, Zeng S, Zhou H, and Jiang H (2014) Inhibition of organic cation transporter 2 and 3 may be involved in the mechanism of the antidepressant-like action of berberine. Prog Neuropsychopharmacol Biol Psychiatry 49:1-6.
55. Sun SY, Wang YQ, Li LP, Wang L, Zeng S, Zhou H, and Jiang HD (2013) Stereoselective interaction between tetrahydropalmatine enantiomers and CYP enzymes in human liver microsomes. Chirality 25:43-47.
56. Sziráki I, Erdo F, Beéry E, Molnár PM, Fazakas C, Wilhelm I, Makai I, Kis E, Herédi-Szabó K, and Abonyi T, et al. (2011) Quinidine as an ABCB1 probe for testing drug interactions at the blood-brain barrier: an in vitro in vivo correlation study. J Biomol Screen 16:886-894.
57. Tan GT, Pezzuto JM, Kinghorn AD, and Hughes SH (1991) Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. J Nat Prod 54:143-154.
58. Tu M, Sun S, Wang K, Peng X, Wang R, Li L, Zeng S, Zhou H, and Jiang H (2013) Organic cation transporter 1 mediates the uptake of monocrotaline and plays an important role in its hepatotoxicity. Toxicology 311:225-230.
59. Wojcikowski J, Haduch A, and Daniel WA (2012) Effect of classic and atypical neuroleptics on cytochrome P450 3A (CYP3A) in rat liver. Pharmacol Rep 64:1411-1418.
60. Wolff JE, Hauch H, Kühl J, Egeler RM, and Jürgens H (1998) Dexamethasone increases hepatotoxicity of MTX in children with brain tumors. Anticancer Res 18 (4B):2895-2899.
61. Xu Q, Li ZX, and Ye ZM (2011) [Nitidine chloride-induced apoptosis of human osteosarcoma cells and its mechanism]. Nan Fang Yi Ke Da Xue Xue Bao 31:361-364.
62. Yonezawa A and Inui K (2011) Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol 81:563-568.
63. Zhang MY, Kagan N, Sung ML, Zaleska MM, and Monaghan M (2008) Sensitive and selective liquid chromatography/tandem mass spectrometry methods for quantitative analysis of 1-methyl-4-phenyl pyridinium (MPP+) in mouse striatal tissue. J Chromatogr B Analyt Technol Biomed Life Sci 874:51-56.
64. Zomorodi K, Carlile DJ, and Houston JB (1995) Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance. Xenobiotica 25:907-916.